Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Lukoil provides Socar with a $1.5 bln loan

10/5/23 LKOH

Polar Lithium plans to commission the first stage of the mine in 2026

10/5/23 GMKN

Polymetal will obtain a license for the Agylkinskoye field

10/5/23 POLY

Gazprom Neft will increase production at a field in Yugra to 8 million tons

10/5/23 SIBN

Seligdar acquired a license for a gold and tin deposit in Chukotka

10/5/23 SELG

DMFA JSC made a final offer for Detsky Mir shares

10/5/23 DSKY

ADNOC accepted an investment decision on gas projects in the UAE with Lukoil's participation

10/5/23 LKOH

Electrozinc shareholders to discuss the company's liquidation

10/5/23 ELTZ

Novabev Group shipments for 9 months decreased by 1.2%

10/5/23 BELU

Astra Group announced the IPO price range

10/5/23 ASTR